Hormonal
A multimodal treatment approach combining metabolic surgery with adjuvant pharmacotherapy (specifically GLP-1 agonists or other anti-obesity drugs) is superior to surgery alone for maintaining long-term glycemic control and remission.
For the best long-term results, Type 2 Diabetes treatment should combine metabolic surgery with ongoing medication (like GLP-1 agonists). This multimodal approach significantly increases the chance of keeping diabetes in remission compared to surgery or medication alone, addressing the fact that surgical benefits can fade over time.
Recent advances in pharmacotherapy, present not only a novel approach to medical therapy but a renewed impetus to investigate what can be achieved through multimodal care... data from the STAMPEDE trial... supports the potential benefit of a combinational approach, with 5-year follow-up data demonstrating 38% RYGB and 24% SG versus 5% in the medication group alone achieving sustained remission.
Why this rating
Supported by RCTs (STAMPEDE) and retrospective/prospective studies on adjuvant drugs.
Source
Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy
Alexis Sudlow et al. · Therapeutic Advances in Endocrinology and Metabolism · 2019
DOI 10.1177/2042018819875407
More from this paper
- Metabolic surgery provides superior short-term remission of type 2 diabetes and greater weight loss compared to pharmacotherapy alone, but long-term remission rates decline significantly over time.Good
- Long-term remission of Type 2 Diabetes following metabolic surgery is not sustained for the majority of patients, with remission rates dropping significantly after 5 years.Good
- Adjuvant pharmacotherapy with anti-obesity medications (AOMs) such as Liraglutide, Lorcaserin, or Naltrexone/Bupropion is effective and well-tolerated for managing weight regain or insufficient weight loss after bariatric surgery.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →